UCSF-Harvard Team Reports Encouraging Results In Drug Study Of Mice W...( Researchers report that four drugs th...)

UCSF-Harvard Team Reports Encouraging Results In Drug Study Of Mice With Cancer

Researchers report that four drugs thought to disrupt the formation of blood vessels that fuel tumor growth have been shown for the first time to be effective at treating spontaneous tumors at distinct stages of progression in mice.

The study, reported in the April 30 issue of Science, provides evidence that these drugs, so-called angiogenesis inhibitors, can act against tumors in a mouse model that more closely resembles the conditions of human tumor development than the models previously used.

It also provides the first indication that the drugs vary in their efficacy depending on the stage of cancer targeted - drugs showed encouraging results when used to treat distinct stages of tumor development, including premalignancy. The model could therefore provide a platform for exploring the potential of perhaps even more effective angiogenesis inhibitors, or combinations of inhibitors, not just for the treatment of cancer, but for prevention, the researchers said.

"We've shown that these drugs have beneficial effects when used to treat mice developing organ-specific cancer in which tumors arise from premalignant lesions in their natural tissue microenvironment, representing an important extension of the evidence for efficacy of angiogenesis inhibition in cancer," said the senior author of the study, Douglas Hanahan, Ph.D., a professor of biochemistry at UCSF.

Many angiogenesis inhibitors are currently being investigated in laboratories around the world. If the results continue to be encouraging, said the lead author of the study, Gabriele Bergers, Ph.D., a visiting postdoctoral fellow in the Department of Biochemistry and Biophysics, and the Hormone Research Institute at UC San Francisco, "the strategy will be to determine which anti-angiogenesis compounds are most effective at which stage of cancer in mouse models, and to develop dosing regimens that are fine-tuned to target these specific stages of disease progression."

The ultimate question,
'"/>

Contact: Jennifer O'Brien
jobrien@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
30-Apr-1999

Page: 1 2 3 4
Related medicine news :

1. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
2. Melanoma Patients Sentinel Lymph Nodes (SLNS) Play A Strong Role In Disease Prognosis, UCSF Study Reports
3. Irritable Bowel Syndrome The Focus Of Three UNC-CH Reports At Digestive Diseases Conference
4. Bone Marrow With Heart And Lung Transplants Reduces Rejection Of Transplanted Organs, Reports University Of Pittsburgh
5. Bone Marrow With Organ Transplants Reduces Rejection Of Transplanted Organs, Reports University Of Pittsburgh
6. BioNumerik Reports Data On Two Novel Supercomputer Engineered Anticancer Agents At 90th Annual Meeting Of The AACR
7. Changes In Levels Of LDLc From Pre- To Post-Menopausal Years Not Valuable Indicator Of Heart Disease, Reports University Of Pittsburgh Researcher
8. Medicare Policy Contradicts Preferred Treatment For Precancerous Skin Conditions, Westwood Squibb Center For Dermatology Research Reports
9. BioNumerik Reports The Supercomputer Supported Discovery Of New, Non-Toxic Chemotherapy Protecting Agent
10. International Study Finds Statins Raise Good Cholesterol, Wake Forest Physician Reports
11. ONYX Pharmaceuticals Reports Phase II Clinical Trial Results At ASCO Meeting

Post Your Comments: